Data compiled by Redley Lamar · ChainSifter Intelligence
1Suppliers
4Customers
2Debt Items
0Related Chains
Source-Backed Evidence Depth
DiaMedica Therapeutics Inc. (DMAC) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
8Total relationships
1Distinct source URLs
4High confidence
0.763Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
DiaMedica Therapeutics Inc. Suppliers
Ticker
Name
Confidence
Evidence
CATALENT-PHARMA-SOLUTIONS-LLC
CATALENT-PHARMA-SOLUTIONS-LLC
92%
We rely on Catalent Pharma Solutions, LLC (Catalent), a contract development and manufacturing organization (CDMO) with proven GMP experience in the manufacturing of recombinant proteins for clinical…
DiaMedica Therapeutics Inc. Customers
Ticker
Name
Confidence
Evidence
CATALENT-PHARMA-SOLUTIONS-LLC
CATALENT-PHARMA-SOLUTIONS-LLC
62%
hose awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures …
DELAWARE-GENERAL-CORPORATION
DELAWARE-GENERAL-CORPORATION
62%
sult of our recent protocol amendment for the ReMEDy2 trial, participants treated with tPA or TNK, (thrombolytic agents) intended to dissolve blood clots, are now eligible for participation if they c…
PHARMACEUTICAL-RESEARCH-ASSOCIATES-GROUP
PHARMACEUTICAL-RESEARCH-ASSOCIATES-GROUP
62%
f AIS where tPA/TNK and/or mechanical thrombectomy are not indicated or medically appropriate. The FDA may grant Fast Track designation to a drug that is intended to treat a serious condition and non…
USA-LLC
USA-LLC
62%
hose awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures …
DiaMedica Therapeutics Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
DMAC-DEBT
Debt stack $212,000
90%
Market cache reports total debt of $212,000.
DMAC-DEBT-9090
Warrants outstanding: 607000
90%
xbrl warrant detail from xbrl 2018-12-31.
DiaMedica Therapeutics Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for DiaMedica Therapeutics Inc..
DiaMedica Therapeutics Inc. Ownership
Holder
Name
Confidence
Evidence
DMAC-OWNER-COOPERMAN-LEON-G
COOPERMAN LEON G
90%
13F overlay lists COOPERMAN LEON G as top holder; 98 tracked holders.
DiaMedica Therapeutics Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
